The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 28, 2023
Filed:
Oct. 16, 2018
Applicant:
Pfizer Inc., New York, NY (US);
Inventors:
Manoj Baburao Charati, Mahwah, NJ (US);
Yoon-Chi Han, New York, NY (US);
Madan Katragadda, Acton, MA (US);
Nicole Melissa Piché-Nicholas, Waltham, MA (US);
Lawrence Nathan Tumey, Vestal, NY (US);
Assignee:
Pfizer, Inc., New York, NY (US);
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 47/68 (2017.01); A61P 35/00 (2006.01); C12N 15/63 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2866 (2013.01); A61K 47/6803 (2017.08); A61K 47/6851 (2017.08); A61P 35/00 (2018.01); C12N 15/63 (2013.01); A61K 2039/505 (2013.01);
Abstract
The present invention provides antibodies that specifically bind to CD123. The invention further relates to immunoconjugates (e.g., antibody-drug conjugates, or ADCs) comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and ADCs for the treatment of a condition associated with cells expressing CD123 (e.g., cancer or autoimmune disease).